Clinical Trial Update: Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD) [Phase 3]

View source ↗

Summary

Phase 3 head-to-head trial comparing Rabeprazole Extended-Release 50 mg with Esomeprazole 40 mg for healing and symptomatic relief in moderate-to-severe erosive…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Erosive Esophagitis
• Gastroesophageal Reflux Disease

Drugs mentioned

• Esomeprazole 40 mg (esomeprazole)
• Rabeprazole Extended Release 50 mg (rabeprazole)

Snippet

Sponsor: Eisai Inc. | Conditions: Gastroesophageal Reflux Disease (GERD) | Phase 3 | Status: COMPLETED | Results posted: 2015-06-23